Choosing the right biological target or a combination of targets is a fundamental task for any successful drug discovery project. All the subsequent efforts -- be it a small molecule hit identification, lead optimization, pharmacokinetic studies, or a clinical trial -- will just be as effective, at the end of the day, as was the initial decision to choose one target or another.
New Tools, Products And Technologies
A multi-year research agreement has just been announced between Takeda Pharmaceuticals (TSE: 4502) and an Artificial Intelligence (AI)-driven computational drug design company Numerate, Inc. Under this contract, Numerate will have to come up with new clinical candidates in the Takeda’s core therapeutic areas: oncology, gastroenterology, and central nervous system disorders.
Chinese biopharmaceutical industry investment landscape has been marked by a new record -- USD $260M Series D investment raised by Innovent Biologics, Inc. exceeded China's previous investment deals for biopharmaceutical industry and became one of the largest biopharmaceutical industry fundraising events in the world for both private and public financing markets in 2016.
Founded in 2009, Pcovery is a Danish biotech startup company involved in drug discovery to fight invasive fungal infections. On November 22, 2016 Pcovery announced the extension of collaboration with a leading producer of building blocks and screening libraries -- Enamine Ltd. In the ongoing drug discovery program, Pcovery will utilize Enamine’s experience in synthesis of small compound libraries and singletons, route scouting, process optimization, and scale-up of lead compounds.